Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.72 |
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | DRD2 | P14416 | 2/20 | 0.63 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | HTR7 | P34969 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3621260 | 0.89 | HTR6 (0.72) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3613116 | 0.89 | HTR6 (0.58) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3620544 | 0.88 | HTR6 (0.71) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3619050 | 0.87 | HTR6 (0.56) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL27810043 | 0.86 | HTR6 (0.56) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3622323 | 0.86 | HTR6 (0.64) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3613339 | 0.85 | HTR6 (0.58) | HTR6HTR1ADRD2HTR2AHTR7 | |
| Iodide SCHEMBL3622153 | 0.84 | HTR6 (0.57) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL3625219 | 0.84 | HTR6 (0.58) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL27788085 | 0.83 | HTR6 (0.57) | HTR6HTR1ADRD2HTR2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101801194-A | Has 5-HT 63 ' the compound that replaces of receptor affinity | MEMORY PHARM CORP | 2010-08-11 | — | — | CN | claimed |
| EP-2184990-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | claimed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | claimed |
| WO-2009023844-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | WO | claimed |
| EP-2184990-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | Memory Pharmaceuticals Corporation (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2009023844-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023844-A2 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | MEMORY PHARMACEUTICALS CORPORATION (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069337-A1 | 3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY | HTR6, HTR3A, HTR3B | HTR6 1/4885HTR1A 4/4885DRD2 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.